Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are promising pharmacologic interventions for obesity.Semaglutide improved body mass index (BMI) and cardiometabolic risk factors in adolescents in a formal trial [1].Drug effectiveness often differs in routine care to trial settings, particularly when used in more heterogeneous populations, yet real-world data from GLP-1RA use in adolescents remains sparse [2][3][4].We evaluated weight and BMI changes with semaglutide use in adolescents and explored patient factors associated with treatment response.
No takes yet. Share an insight, caveat, or question.
Cimador et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: